NovoCure Stock Price, News & Analysis (NASDAQ:NVCR)

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1-year target prices for NovoCure's stock. Their NVCR share price targets range from $25.00 to $51.00. On average, they predict the company's share price to reach $45.29 in the next twelve months. This suggests a possible upside of 262.3% from the stock's current price.
View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts.

NovoCure's stock was trading at $73.35 at the start of the year. Since then, NVCR stock has decreased by 83.0% and is now trading at $12.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our NVCR earnings forecast.

NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, October, 26th. The medical equipment provider reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.05. The medical equipment provider had revenue of $127.30 million for the quarter, compared to analysts' expectations of $128.75 million. NovoCure had a negative trailing twelve-month return on equity of 46.89% and a negative net margin of 39.14%. The firm's revenue for the quarter was down 2.8% on a year-over-year basis. During the same period last year, the firm posted ($0.25) earnings per share.

ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH).

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ).

NovoCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), Baillie Gifford & Co. (6.38%), Morgan Stanley (1.02%), Palo Alto Investors LP (0.62%), Charles Schwab Investment Management Inc. (0.51%) and Northern Trust Corp (0.41%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends.

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.